Search research articles
Contact Us
Filters
Showing results (11-20 of 238) with videos related to
Page
of 24
Sort By:
JAMA
|
February 18, 2020
Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome: Time to Overhaul Drug Trials in ARDS?
Manu Shankar-Hari, Carolyn S Calfee
Critical Care Medicine
|
October 14, 2017
Just Because Things Are Not Different, Does Not Mean They Are the Same: Biomarker Patterns in Acute Respiratory Distress Syndrome
Manu Shankar-Hari, Gordon D Rubenfeld
Expert Review of Molecular Diagnostics
|
March 22, 2014
How might a diagnostic microRNA signature be used to speed up the diagnosis of sepsis?
Manu Shankar-Hari, Graham M Lord
Current Infectious Disease Reports
|
October 7, 2016
Understanding Long-Term Outcomes Following Sepsis: Implications and Challenges
Manu Shankar-Hari, Gordon D Rubenfeld
Current Opinion in Critical Care
|
July 24, 2019
Population enrichment for critical care trials: phenotypes and differential outcomes
Manu Shankar-Hari, Gordon D Rubenfeld
American Journal of Respiratory and Critical Care Medicine
|
February 2, 2017
Acute Respiratory Distress Syndrome Phenotypes and Identifying Treatable Traits. The Dawn of Personalized Medicine for ARDS
Manu Shankar-Hari, Daniel F McAuley
Chest
|
February 20, 2021
Immunological Subpopulations Within Critically Ill COVID-19 Patients
Julie Kay Wilson, Manu Shankar-Hari
JAMA
|
October 26, 2018
Lessons From ARDS for Non-ARDS Research: Remembrance of Trials Past
Gordon D Rubenfeld, Manu Shankar-Hari
Thorax
|
July 19, 2017
Divide and conquer: identifying acute respiratory distress syndrome subphenotypes
Manu Shankar-Hari, Daniel F McAuley
Critical Care Medicine
|
May 16, 2018
Race, Ethnicity, and Sepsis: Beyond Adjusted Odds Ratios
Manu Shankar-Hari, Gordon D Rubenfeld
Page
of 24
Search research articles
Search
Showing results (11-20 of 238) with videos related to
Sort By:
Page
of 24
JAMA
|
February 18, 2020
Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome: Time to Overhaul Drug Trials in ARDS?
Manu Shankar-Hari, Carolyn S Calfee
Critical Care Medicine
|
October 14, 2017
Just Because Things Are Not Different, Does Not Mean They Are the Same: Biomarker Patterns in Acute Respiratory Distress Syndrome
Manu Shankar-Hari, Gordon D Rubenfeld
Expert Review of Molecular Diagnostics
|
March 22, 2014
How might a diagnostic microRNA signature be used to speed up the diagnosis of sepsis?
Manu Shankar-Hari, Graham M Lord
Current Infectious Disease Reports
|
October 7, 2016
Understanding Long-Term Outcomes Following Sepsis: Implications and Challenges
Manu Shankar-Hari, Gordon D Rubenfeld
Current Opinion in Critical Care
|
July 24, 2019
Population enrichment for critical care trials: phenotypes and differential outcomes
Manu Shankar-Hari, Gordon D Rubenfeld
American Journal of Respiratory and Critical Care Medicine
|
February 2, 2017
Acute Respiratory Distress Syndrome Phenotypes and Identifying Treatable Traits. The Dawn of Personalized Medicine for ARDS
Manu Shankar-Hari, Daniel F McAuley
Chest
|
February 20, 2021
Immunological Subpopulations Within Critically Ill COVID-19 Patients
Julie Kay Wilson, Manu Shankar-Hari
JAMA
|
October 26, 2018
Lessons From ARDS for Non-ARDS Research: Remembrance of Trials Past
Gordon D Rubenfeld, Manu Shankar-Hari
Thorax
|
July 19, 2017
Divide and conquer: identifying acute respiratory distress syndrome subphenotypes
Manu Shankar-Hari, Daniel F McAuley
Critical Care Medicine
|
May 16, 2018
Race, Ethnicity, and Sepsis: Beyond Adjusted Odds Ratios
Manu Shankar-Hari, Gordon D Rubenfeld
Page
of 24